Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

As European markets navigate a period of uncertainty marked by economic contractions and fluctuating retail sales, investors are increasingly focused on identifying opportunities that offer attractive valuations. In this context, finding stocks trading below their estimated intrinsic values can be a prudent strategy for those looking to capitalize on potential market inefficiencies.

Top 10 Undervalued Stocks Based On Cash Flows In Europe

Name Current Price Fair Value (Est) Discount (Est) Talgo (BME:TLGO) €2.69 €5.21 48.4% Sanoma Oyj (HLSE:SANOMA) €9.10 €18.13 49.8% Rheinmetall (XTRA:RHM) €1207.20 €2368.27 49% PCC Rokita (WSE:PCR) PLN67.30 PLN132.17 49.1% Netcompany Group (CPSE:NETC) DKK340.20 DKK666.23 48.9% Hanza (OM:HANZA) SEK166.60 SEK330.80 49.6% elumeo (XTRA:ELB) €1.73 €3.41 49.2% Cint Group (OM:CINT) SEK5.75 SEK11.30 49.1% B&S Group (ENXTAM:BSGR) €5.85 €11.66 49.8% Bonesupport Holding (OM:BONEX) SEK225.40 SEK435.98 48.3%

Click here to see the full list of 203 stocks from our Undervalued European Stocks Based On Cash Flows screener.

Let's uncover some gems from our specialized screener.

ABIVAX Société Anonyme

Overview: ABIVAX Société Anonyme is a clinical-stage biotechnology company focused on developing therapeutics to stabilize the immune response in chronic inflammatory diseases, with a market cap of €6.84 billion.

Operations: The company generates revenue of €4.92 million from its research and development of pharmaceutical products aimed at stabilizing the immune response in chronic inflammatory diseases.

Estimated Discount To Fair Value: 40.9%

ABIVAX Société Anonyme is trading at €85.8, significantly below its estimated future cash flow value of €145.25, suggesting it may be undervalued based on discounted cash flow analysis. Despite recent shareholder dilution and a volatile share price, the company shows promising revenue growth forecasts of 59% annually, outpacing the French market average. Positive Phase 3 trial results for obefazimod in ulcerative colitis and plans for regulatory submissions further bolster its potential value proposition.

Upon reviewing our latest growth report, ABIVAX Société Anonyme's projected financial performance appears quite optimistic. Unlock comprehensive insights into our analysis of ABIVAX Société Anonyme stock in this financial health report.ENXTPA:ABVX Discounted Cash Flow as at Jun 2026

Helvetia Baloise Holding

Overview: Helvetia Baloise Holding AG operates in the life and non-life insurance, as well as reinsurance sectors, with a market cap of CHF19.75 billion.

Operations: The company generates revenue from three primary segments: life insurance at CHF2.10 billion, non-life insurance at CHF7.46 billion, and reinsurance contributing CHF509.50 million.

Story Continues

Estimated Discount To Fair Value: 38.3%

Helvetia Baloise Holding, trading at CHF199.4, is significantly undervalued relative to its estimated future cash flow value of CHF323.1. Despite recent shareholder dilution and a dividend not fully covered by free cash flows, the company reported net income growth to CHF552.3 million for 2025 and forecasts strong earnings growth of 29.6% annually, surpassing the Swiss market average. Recent fixed-income offerings enhance its financial flexibility amidst these dynamics.

According our earnings growth report, there's an indication that Helvetia Baloise Holding might be ready to expand. Click here to discover the nuances of Helvetia Baloise Holding with our detailed financial health report.SWX:HBAN Discounted Cash Flow as at Jun 2026

RENK Group

Overview: RENK Group AG specializes in the design, engineering, production, testing, and servicing of customized drive systems across various global regions including Asia, Germany, the United States, Africa, Australia, Oceania, and other European countries with a market cap of €5.16 billion.

Operations: The company's revenue segments include Slide Bearings at €127.49 million, Marine & Industry at €372.50 million, and Vehicle Mobility Solutions at €891.45 million.

Estimated Discount To Fair Value: 39.9%

RENK Group, trading at €51.57, is undervalued compared to its estimated future cash flow value of €85.75. The company's earnings are projected to grow significantly at 24.4% annually, outpacing the German market's 17.2% growth forecast. Despite high debt levels, RENK reported substantial first-quarter net income growth and confirmed revenue expectations exceeding €1.5 billion for 2026, indicating robust financial performance amidst favorable analyst price targets predicting a 32.1% rise in stock price.

The analysis detailed in our RENK Group growth report hints at robust future financial performance. Get an in-depth perspective on RENK Group's balance sheet by reading our health report here.XTRA:R3NK Discounted Cash Flow as at Jun 2026

Next Steps

Reveal the 203 hidden gems among our Undervalued European Stocks Based On Cash Flows screener with a single click here. Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks. Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.

Curious About Other Options?

Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ENXTPA:ABVX SWX:HBAN and XTRA:R3NK.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Während das europäische Markt durch stabile Zinssätze und geopolitische Unsicherheiten geprägt ist, hat der pan-europäische STOXX Europe 600 Index eine stabile Kursentwicklung aufrechterhalten. Dies spiegelt vorsichtig optimistische Stimmung bei positiver Earnings-Momentum wider. In diesem Umfeld wird es für Investoren wichtig sein, potenziell unterbewertete Aktien zu identifizieren, die möglicherweise einen Wert relativ zum geschätzten Wert bieten.